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Preferences for cancer investigation: a vignette-based study 
of primary-care attendees
Jonathan Banks, Sandra Hollinghurst, Lin Bigwood, Tim J Peters, Fiona M Walter, Willie Hamilton
Summary
Background The UK lags behind many European countries in terms of cancer survival. Initiatives to address this 
disparity have focused on barriers to presentation, symptom recognition, and referral for specialist investigation. 
Selection of patients for further investigation has come under particular scrutiny, although preferences for referral 
thresholds in the UK population have not been studied. We investigated preferences for diagnostic testing for 
colorectal, lung, and pancreatic cancers in primary-care attendees.
Methods In a vignette-based study, researchers recruited individuals aged at least 40 years attending 26 general 
practices in three areas of England between Dec 6, 2011, and Aug 1, 2012. Participants completed up to three 
of 12 vignettes (four for each of lung, pancreatic, and colorectal cancers), which were randomly assigned. The 
vignettes outlined a set of symptoms, the risk that these symptoms might indicate cancer (1%, 2%, 5%, or 10%), the 
relevant testing process, probable treatment, possible alternative diagnoses, and prognosis if cancer were identiﬁ ed. 
Participants were asked whether they would opt for diagnostic testing on the basis of the information in the vignette.
Findings 3469 participants completed 6930 vignettes. 3052 individuals (88%) opted for investigation in their ﬁ rst 
vignette. We recorded no strong evidence that participants were more likely to opt for investigation with a 1% increase 
in risk of cancer (odds ratio [OR] 1·02, 95% CI 0·99–1·06; p=0·189), although the association between risk and opting 
for investigation was strong when colorectal cancer was analysed alone (1·08, 1·03–1·13; p=0·0001). In multivariable 
analysis, age had an eﬀ ect in all three cancer models: participants aged 60–69 years were signiﬁ cantly more likely to opt 
for investigation than were those aged 40–59 years, and those aged 70 years or older were less likely. Other variables 
associated with increased likelihood of opting for investigation were shorter travel times to testing centre (colorectal and 
lung cancers), a family history of cancer (colorectal and lung cancers), and higher household income (colorectal and 
pancreatic cancers).
Interpretation Participants in our sample expressed a clear preference for diagnostic testing at all risk levels, and 
individuals want to be tested at risk levels well below those stipulated by UK guidelines. This willingness should be 
considered during design of cancer pathways, particularly in primary care. The public engagement with our study 
should encourage general practitioners to involve patients in referral decision making.
Funding The National Institute for Health Research Programme Grants for Applied Research programme.
Introduction
More than one in three people in the UK will develop 
cancer during their lifetime.1 Although cancer mortality in 
the UK has improved in the past 15 years,2 it is still worse 
than the average across Europe.3 Several initiatives have 
been introduced in the UK to address this issue, such as 
the Cancer Reform Strategy and the National Awareness 
and Early Diagnosis Initiative.4 Earlier diagnosis is 
thought to be one of the main ways to improve survival, 
mainly by improved selection of patients for further 
investigation.5 Almost 90% of patients with cancer are 
diagnosed after experiencing symptoms, most of whom 
present to primary-care facilities.6 Selection of patients for 
further investigation is not straightforward: over-
investigation has clinical and ﬁ nancial costs, and 
underinvestigation risks a delay in diagnosis and therefore 
has clinical and medicolegal costs. This selection is made 
by clinicians, who have largely guided provision of cancer 
diagnostic services. However, other groups have a 
legitimate interest in this decision: providers of cancer 
diagnostic services, govern ments, taxpayers, insurers, 
and—most import antly—patients.
Most common symptoms of cancer can also represent 
benign disease. When deciding whether to investigate for 
possible cancer, general practitioners use their experience 
and national guidelines, especially the UK National 
Institute for Health and Care Excellence (NICE) guidance 
that was issued in 2005.7 This guidance also underpins 
the provision of 2-week-wait clinics, in which patients are 
guaranteed to be seen within 2 weeks. NICE guidance 
describes symptoms or combinations of symptoms and 
signs deemed worthy of investigation. By implication, 
when investigation is recommended by the guidance, the 
likelihood of the patient having cancer is high enough to 
justify it, although no explicit risk threshold warranting 
investigation for cancer has been reported in the UK or 
any other national guidance.8 The percentage of patients 
referred to 2-week-wait clinics who are subsequently 
shown to have cancer varies between cancer sites, 
geographical areas, and general practitioners.9 However, 
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only a quarter of cancers in the UK are diagnosed 
in 2-week-wait clinics, with other patients presenting as 
emergencies or referred to other specialist services.10,11 
Research in primary care has provided estimates of the 
risk of cancer for many symptoms, with several symptoms 
recommended by NICE as indicating a high likelihood of 
cancer: few of the NICE recommendations equate to risks 
of less than 5%.12,13
NICE referral guidance strongly recommends that the 
patient participate in decisions about testing,7 although 
little research has been done into diagnostic preferences 
of patients. Previous research has focused on treatment 
or follow-up options,14 preferences for screening,15 
predictive investigation,16 or the sharing of risk 
information.17 Patients certainly fear cancer—more so 
than they do knife crime, Alzheimer’s disease, and job 
loss18—but how likely they are to choose investigation for 
cancer when provided with the relevant information 
about cancer risk, the details of investigation, and 
possible outcomes is unknown. We aimed to establish 
the likelihood that individuals would choose to be tested 
for cancer at various levels of risk.
Methods
Study design and participants
In a vignette-based study, we recruited 26 general practices 
in three areas of England (Bristol and south Gloucester-
shire, Devon, and the east of England) to include a broad 
range of urban and rural locations and varying levels of 
socioeconomic status (number of practices and speciﬁ c 
practices not prespeciﬁ ed). We compared mean practice 
size and Index of Multiple Deprivation score with 
overall means from the National Public Health Observatory, 
and ethnic origin of patients with 2009 means from the 
Oﬃ  ce of National Statistics.
In these general practices, researchers recruited 
attendees aged at least 40 years in waiting areas at 
diﬀ erent times of the day and week between Dec 6, 2011, 
and Aug 1, 2012. We did a test–retest exercise in one 
additional practice, with 48 volunteers (of a recruitment 
target of 50; same inclusion criteria) who agreed to 
return 2 weeks later, to complete identical vignettes to 
their ﬁ rst exercise. These participants were oﬀ ered 
£10 shopping vouchers.
We obtained ethics approval from the South West 
(Southmead) National Research Ethics Service committee 
(ref 11/SW/0055). Participants provided oral informed 
consent.
Procedures
We chose to compare colorectal, lung, and pancreatic 
cancers, because they diﬀ er in terms of symptoms, type 
of test, treatment, and prognosis. We developed 12 separate 
vignettes (ie, descriptions of hypothetical situations), 
with four for each of the three cancers (table 1 
shows symptoms extracts; appendix shows full 
description of vignettes). The content of the vignettes 
was informed by NICE guidelines, qualitative interviews 
with patients referred for diagnostic tests for the three 
cancers,19 and clinical experience.20–22 Each vignette 
contained a description of symptoms, the risk that these 
symptoms might indicate cancer (both numerically and 
pictorially), information about the relevant diagnostic 
test, probable treatment, possible alternative diagnoses, 
and an indication of the prognosis if cancer were 
identiﬁ ed. The vignette culminated in a brief summary 
of information and asked the respondent whether they 
would choose diagnostic testing at that point, or would 
not want to be tested (the exact wording being “YES—I 
would choose to be tested” or “NO—I would not want to 
be tested now”). After this choice, participants were 
asked for the main reason for their decision with a list of 
options that were informed by qualitative interviews,19 
questionnaires previously used in cancer research,23 and 
the cognitive interviewing phase.
We reﬁ ned the vignettes in two rounds of cognitive 
interviewing using the verbal probing method24 
with 18 members of patient groups from three general 
practices. We asked 13 of these participants whether they 
understood the questions and the information. We 
recorded responses systematically and collated them. 
After redesign, we tested the questionnaire again 
on ﬁ ve additional participants followed by 1 week of 
piloting in which the questionnaire was administered as 
per protocol in a general practice waiting room to check 
recruitment method, functionality of equipment, and 
data recording.
Participants could complete up to three vignettes, 
which were delivered on an electronic touchscreen tablet 
computer. The software developed for the survey selected 
the ﬁ rst vignette randomly from all 12 possibilities, the 
second from the two remaining cancers (eight 
possibilities), and the third from the remaining cancer 
(four possibilities). We also gathered information about 
participant characteristics, such as age, sex, income, 
education, employment status, ethnic origin, experience 
of cancer, and convenience of the nearest main hospital.
For study protocol see http://
www.discovery-programme.org/
pdfs/PIVOT%20protocol%20
version%201%2001.11.2010.pdf
See Online for appendix
Colorectal cancer Lung cancer Pancreatic cancer
1% Diarrhoea on most days Coughing on most days
Unusually tired
Some stomach pain on most days
Lost a few pounds (~1·5–3 kg) in 
weight
2% Diarrhoea and stomach pain 
on most days
Coughing on most days
A little out of breath walking up hills
Lost a few pounds (~1·5–3 kg) in 
weight
Some stomach pain on most days
Lost half a stone (3·2 kg) in 
weight
5% Unusually tired
A blood test shows anaemia
Coughing on most days
Coughed blood once
Continuous stomach pain
Lost half a stone (3·2 kg) in 
weight
10% Intermittent bleeding from the 
back passage (rectal bleeding)
A blood test shows anaemia
Coughing on most days
Coughed blood a few times
Lost half a stone (3·2 kg) in weight
Continuous stomach pain
Lost 1 stone (6·4 kg) in weight
All symptoms last 6 weeks.
Table 1: Symptoms described in the vignettes, by risk level
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Statistical analysis
We estimated that 80% of participants given a 10% risk 
vignette would opt for investigation, and 60% of those 
given 1% risk would do so. With a two-sided 5% alpha 
and 90% power, we estimated that we would 
need 119 participants in each group, or 1428 overall.
In addition to descriptive statistics, we used logistic 
regression for the main question (ie, whether or not to be 
tested), with opting for investigation as the outcome 
variable. The explanatory variables were cancer site, risk 
level (as a continuous variable), age group, sex, ethnic 
origin, income band, education, employment, previous 
diagnosis of cancer, cancer diagnosis in a family member 
or close friend, convenience of hospital, and travel time to 
hospital. In this analysis, we used only the ﬁ rst completed 
vignette from each participant because data were available 
for all participants, thus avoiding possible diﬀ erential 
selection bias for subsequent vignettes.
We then developed separate models for each cancer, 
using all (ﬁ rst, second, or third) responses for that cancer. 
Because participants who completed more than one 
vignette always had a diﬀ erent cancer for the later 
vignettes, concerns about selection bias in the analysis of 
each cancer separately were eliminated. Initially, we 
entered every possible explanatory variable into uni-
variable analysis to establish the strength of the 
association between it and opting for investigation, and 
those with a p value of less than 0·2 were retained for 
multivariable analysis. The ﬁ rst multivariable model 
contained only variables with a univariable p value of less 
than 0·05; we then added the other variables sequentially, 
repeating the process until only variables with p values of 
less than 0·05 after adjustment for all other variables in 
the model were present.
A supplementary analysis used k-fold cross validation 
with risk level as the only predictor variable in the base 
model and four other explanatory variables as additional 
predictors. We tested these variables sequentially, omitting 
variables in turn that did not seem to contribute to the 
model. We also considered the eﬀ ect of missing data on 
the regression models by omitting any variable with more 
than 5% of missing data and examining the change in 
results. Our ﬁ nal validation check was to use intracluster 
correlation coeﬃ  cients to investigate the degree of 
clustering of the outcome variable across the 26 practices 
and the six researchers involved in data collection.   
We used Stata (versions 12 and 13) for all analyses. We 
did the test–retest analysis on the ﬁ rst vignettes and used 
percentage comparisons for participant characteristics 
and κ statistics for the vignette components.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all data in the study and had ﬁ nal responsibility 
for the decision to submit for publication.
Participants 
(n=3469)
Age (years)
40–59 1519 (44%)
60–69 945 (27%)
≥70 988 (28%)
Missing 17 (<1%)
Sex
Men 1457 (42%)
Women 2004 (58%)
Missing 8 (<1%)
Annual income
<£10 000 720 (21%)
£10 000–25 000 1166 (34%)
>£25 000 1072 (31%)
Missing 511 (15%)
Ethnic origin
White British 3096 (89%)
Other 357 (10%)
Missing 16 (<1%)
Highest educational qualiﬁ cation
None 1001 (29%)
General Certiﬁ cate of Secondary Education (GCSE) 
or equivalent
781 (23%)
Vocational or A level 850 (25%)
Degree and higher 756 (22%)
Missing 81 (2%)
Employment
Retired 1673 (48%)
Not in paid employment 379 (11%)
Working part time 607 (17%)
Working full time 787 (23%)
Missing 23 (1%)
Previously diagnosed with cancer
Yes 522 (15%)
No 2941 (85%)
Missing 6 (<1%)
Family member or close friend previously diagnosed with cancer
Yes 2597 (75%)
No 868 (25%)
Missing 4 (<1%)
Convenience of hospital
Very convenient 1388 (40%)
Quite convenient 1621 (47%)
Quite inconvenient 323 (9%)
Very inconvenient 129 (4%)
Missing 8 (<1%)
Travel time to hospital
<0·5 h 1759 (51%)
0·5–1 h 1458 (42%)
>1 h 246 (7%)
Missing 6 (<1%)
Data are n (%). 
Table 2: Characteristics of participants
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Results
The mean number of patients registered in each of 
the 26 general practices was 11 505 (range 4161–19 597; 
SD 3477), which is higher than the overall mean number 
per practice in England in 2011 of 6935.25 The mean Index of 
Multiple Deprivation score was 18·3 (range 4·7–39·2; 
SD 8·0), compared with an overall English mean of 21·7 in 
2010.25 The mean percentage of non-white British patients 
in each practice was 4·3% (SD 4·4), compared with a mean 
for England and Wales of 12·1%.26
The study was popular and individuals were recruited 
much more quickly than had been expected. Because our 
estimated eﬀ ect sizes were not robust, we continued the 
study to use our full researcher time. 3469 individuals 
participated, completing 6930 vignettes. 1415 individuals 
declined to participate.
The age and sex proﬁ les of our sample (table 2) were 
similar to that of the consulting population in England.27 
However, the proportion of men aged 40–59 years in our 
study population (589 [17%]) was lower than in the overall 
population of England (27%) and the proportion of women 
aged 60–69 years (526 [15%]) was higher than in the overall 
population (11%).28 The proportion of participants 
aged 70 years or more in our study population (28%; 
table 2) was also higher than in the overall population 
(24%).28 The respondents were largely of white British 
ethnic origin and nearly half were retired (table 2). 15% 
had previously been diagnosed with cancer (table 2), 
which is higher than the estimate of 13% for individuals 
older than 65 years in the UK (owing to scarce data on this 
subject, this age group represents the most meaningful 
comparison available).29 For most characteristics, only a 
small proportion of data was missing (table 2).
Overall, 88% of participants opted for investigation in 
the ﬁ rst vignette (table 3). The proportion was slightly 
lower in the lowest risk group and higher in the highest 
risk group (table 3), but the diﬀ erence was small and could 
largely be explained by a risk gradient for colorectal cancer 
(table 3). This pattern was consistent across responses to 
the ﬁ rst, second, and third vignettes (data not shown).
Colorectal cancer Lung cancer Pancreatic cancer All three cancers (ﬁ rst vignette 
only)
Responses Choose to 
be tested
Responses Choose to 
be tested
Responses Choose to 
be tested
Responses Choose to 
be tested
1% 572 462 (81%) 581 533 (92%) 582 525 (90%) 898 782 (87%)
2% 569 485 (85%) 571 531 (93%) 580 527 (91%) 838 738 (88%)
5% 580 496 (86%) 589 543 (92%) 572 526 (92%) 873 764 (88%)
10% 570 508 (89%) 582 537 (92%) 582 529 (91%) 860 768 (89%)
All 2291 1951 (85%) 2323 2144 (92%) 2316 2107 (91%) 3469 3052 (88%)
Table 3: Number of participants who would choose to be investigated, by cancer and risk level
Colorectal cancer Lung cancer Pancreatic cancer
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Risk 1·08 (1·03–1·13) 0·0001 ·· ·· ·· ··
Age (years) 0·0347 <0·0001 <0·0001
40–59* 1 ·· 1 ·· ·· ··
60–69 1·29 (0·92–1·82) ·· 1·32 (0·86–2·03) ·· 2·56 (0·94–7·00) ··
≥70 0·81 (0·59–1·11) ·· 0·54 (0·38–0·76) ·· 0·35 (0·13–0·99) ··
Travel time to hospital (h) 0·0004 0·0032 ··
<0·5* 1 ·· 1 ·· ·· ··
0·5–1 0·78 (0·59–1·03) ·· 0·93 (0·67–1·30) ·· ·· ··
>1 0·39 (0·22–0·68) ·· 0·41 (0·25–0·67) ·· ·· ··
Family member or close friend 
previously diagnosed with cancer
0·0266 0·0006 ··
Yes* 1 ·· 1 ·· ·· ··
No 0·72 (0·53–0·96) ·· 0·55 (0·40–0·77) ·· ·· ··
Household income 0·0025 ·· 0·0001
<£10 000* 1 ·· ·· ·· 1 ··
£10 000–25 000 1·31 (0·95–1·81) ·· ·· ·· 2·63 (0·97–7·16) ··
>£25 000 1·85 (1·26–2·71) ·· ·· ·· 3·80 (1·09–13·26) ··
OR=odds ratio. *Reference category.
Table 4: Multivariable analysis for each cancer
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The logistic regression analysis, combining all three 
cancers and controlling for participant characteristics, 
identiﬁ ed no strong evidence that participants were more 
likely to opt for investigation with a 1% increase in risk 
that symptoms indicated cancer (odds ratio [OR] 1·02, 
95% CI 0·99–1·06; p=0·189). Compared with colorectal 
cancer, after adjustment for risk, participants were more 
likely to opt for investigation for lung cancer (2·66, 
95% CI 1·99–3·56, p<0·0001) and pancreatic cancer 
(1·96, 1·48–2·60, p<0·0001). We recorded no evidence of 
an overall interaction between risk and cancer site 
(p=0·183). However, when the types of cancers were 
analysed separately, risk did have an eﬀ ect on whether 
investigation was chosen for colorectal cancer (table 4).
Age had an eﬀ ect in all three cancer models: 
participants aged 60–69 years were more likely to opt for 
investigation for all three cancers than were those 
aged 40–59 years, and those in the oldest group 
(≥70 years) were least likely to opt for investigation 
(table 4). Further investigation into whether attitude to 
risk was aﬀ ected by age showed weak evidence of an 
eﬀ ect overall (pinteraction=0·10), with substantial variation 
across the diﬀ erent cancers. With controlling for all other 
factors, participants in the youngest age group 
(40–59 years) were more likely to opt for investigation as 
risk increased for colorectal cancer (OR 1·07, 
95% CI 1·01–1·13) and for pancreatic cancer (1·10, 
1·01–1·17). Conversely, participants in the oldest group 
(≥70 years) were less likely to opt for investigation as risk 
increased for lung cancer (OR 0·96, 95% CI 0·88–1·04) 
and for pancreatic cancer (0·93, 0·87–1·01), although the 
conﬁ dence intervals were wide and include the null 
value. Other variables associated with increased 
likelihood of opting for investigation were shorter travel 
times to testing centre (colorectal and lung cancers), a 
family member or close friend previously diagnosed with 
cancer (colorectal and lung cancers), and higher 
household income (colorectal and pancreatic cancers; 
table 4).
The k-fold cross validation results for all three cancer 
sites produced ﬁ nal models including the same variables 
as those in the original models, with almost identical 
regression coeﬃ  cients (data not shown). Table 5 shows 
the distribution of participants’ responses for each 
variable identiﬁ ed in the logistic regression. We 
examined the potential bias of missing data in relation to 
income by omitting the variable from the two ﬁ nal 
models for colorectal and pancreatic cancers in table 4, 
with almost identical results for risk level and the other 
variables (ie, omission of this variable from the models 
made no diﬀ erence to the models themselves). We noted 
negligible intracluster correlation of the preference for 
investigation by general practice and by researcher who 
enrolled the individual for all vignettes, and for each 
cancer site separately (data not shown).
The main reasons cited by participants opting for 
investigation in the ﬁ rst vignette were peace of mind, 
early detection, and a family history of cancer, with little 
variation across the three cancers (table 6). The main 
reasons cited by those choosing not to be investigated 
Colorectal cancer Lung cancer Pancreatic cancer All three cancers (ﬁ rst 
vignette only)
Responses Choose to 
be tested
Responses Choose to 
be tested
Responses Choose to 
be tested
Responses Choose to 
be tested
Age (years)
40–59 1061 917 (86%) 1076 1004 (93%) 1083 1002 (93%) 1519 1372 (90%)
60–69 641 563 (88%) 638 605 (95%) 640 601 (94%) 945 861 (91%)
≥70 580 463 (80%) 598 524 (88%) 583 496 (85%) 988 805 (81%)
All 2282 1943 (85%) 2312 2133 (92%) 2306 2099 (91%) 3452 3038 (88%)
Travel time to hospital (h)
<0·5 1204 1052 (87%) 1224 1143 (93%) 1220 1126 (92%) 1759 1586 (90%)
0·5–1 943 798 (85%) 946 874 (92%) 943 853 (90%) 1458 1272 (87%)
>1 143 101 (71%) 150 125 (83%) 149 124 (83%) 246 189 (77%)
All 2290 1951 (85%) 2320 2142 (92%) 2312 2103 (91%) 3463 3047 (88%)
Family member or close friend previously diagnosed with cancer
Yes 1739 1507 (87%) 1778 1660 (93%) 1769 1625 (92%) 2597 2317 (89%)
No 550 443 (81%) 545 484 (89%) 545 481 (88%) 868 733 (84%)
All 2289 1950 (85%) 2323 2144 (92%) 2314 2106 (91%) 3465 3050 (88%)
Annual income
<£10 000 450 357 (79%) 445 403 (91%) 443 376 (85%) 720 595 (83%)
£10 000–25 000 759 642 (85%) 770 715 (93%) 746 685 (92%) 1166 1035 (89%)
>£25 000 806 721 (89%) 806 758 (94%) 825 777 (94%) 1072 985 (92%)
All 2015 1720 (85%) 2021 1876 (93%) 2014 1838 (91%) 2958 2615 (88%)
Table 5: Number of participants who would choose to be investigated, by cancer and variables identiﬁ ed in the multivariable analysis
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were low risk of cancer, low risk at present age, and 
would rather not know (table 6). Reasons for opting for 
no investigation varied between the three cancers 
(table 6)—eg, much higher proportions cited an 
unpleasant test or harmful test for colorectal cancer than 
for lung and pancreatic cancers.
The primary research question of whether the 
participant chose to undergo diagnostic tests for cancer 
showed excellent test–retest consistency, with a κ statistic 
of 0·878 (>0·75 is deemed excellent). Participants’ 
reasons for their choice produced κ statistics of 0·584 for 
those who would opt for investigation and 0·667 for 
those who would not opt for investigation, which are 
both in the fair to good range (0·4–0·75).30 The social and 
economic status data showed reliable test–retest 
consistency: six of ten questions returned higher 
than 90% agreement, three were between 80% and 89%, 
and one (hospital travel time) was 69%.
Discussion
To our knowledge, ours is the ﬁ rst study of public 
preferences for cancer investigation (panel). 88% of 
participants would opt for investigation when given a 
realistic scenario of symptoms that could indicate cancer, 
along with the risk of cancer these symptoms posed, plus 
a description of the relevant investigation and likely 
outcomes. Despite the strong preference for testing, the 
proportion who would opt for testing increased with risk. 
Although this risk gradient was identiﬁ ed in the analysis 
incorporating all three cancers, it was primarily driven by 
the ﬁ ndings for colorectal cancer, for which participants 
seemed to make a trade-oﬀ  between the invasiveness of 
the colonoscopy and the risk of cancer. Age also seemed to 
aﬀ ect responses, with the preference for investigation 
highest in individuals aged 60–69 years and lowest in 
those aged at least 70 years.
The willingness for testing shown in our study far 
exceeds what is actually being oﬀ ered by the National 
Health Service. Similarly, Slevin and colleagues31 showed 
that patients with cancer were more likely to choose 
chemotherapy than clinicians were, even when beneﬁ ts 
were small. Participants in our study might have simply 
opted for a free test, an idea which is supported by the 
fact that the proportion opting for investigation did not 
vary by risk for lung and pancreatic cancer. The vignettes 
might not have been suﬃ  ciently sensitive to diﬀ erent 
risk levels. However, the diﬀ erences by risk level for 
colorectal cancer and by age group suggest that 
participants considered their responses.
The four vignettes for colorectal cancer were all in line 
with NICE guidance for urgent referral (because of 
the 6 weeks of diarrhoea), although many symptoms 
with a low risk of cancer (1–5%) are not included in NICE 
guidance.12,13 For lung cancer, a chest radiograph is 
recommended by NICE when a patient has a persistent 
cough (deﬁ ned as lasting at least 3 weeks). Again, many 
symptoms of lung cancer fall into the 1–5% bracket, but 
NICE guidance suggests that tests should be done only if 
cough is present for 3 weeks.7,21,32 The pancreatic scenarios 
used in our study might not be in line with NICE 
guidance (which largely concentrates on jaundice).
Even with these caveats, the proportion of patients opting 
for investigation at even a 1% risk of cancer is substantially 
diﬀ erent from the conversion rate (the percentage of 
All three cancers (ﬁ rst 
vignette only)
Colorectal cancer Lung cancer Pancreatic cancer
Main reason for choosing to be tested
Peace of mind 1255/3052 (41%) 723/1951 (37%) 806/2144 (38%) 832/2107 (39%)
Early detection 1191/3052 (39%) 872/1951 (45%) 890/2144 (42%) 877/2107 (42%)
Family history of cancer 306/3052 (10%) 212/1951 (11%) 204/2144 (10%) 195/2107 (9%)
At risk from age 107/3052 (4%) 63/1951 (3%) 61/2144 (3%) 66/2107 (3%)
No reason given 77/3052 (3%) 47/1951 (2%) 58/2144 (3%) 62/2107 (3%)
Test is straightforward 56/3052 (2%) 10/1951 (1%) 58/2144 (3%) 43/2107 (2%)
Pressure from family or friends 34/3052 (1%) 20/1951 (1%) 22/2144 (1%) 21/2107 (1%)
At risk from lifestyle 26/3052 (1%) 4/1951 (<1%) 45/2144 (2%) 11/2107 (1%)
Main reason for choosing not to be tested
Low risk of cancer 103/417 (25%) 69/340 (20%) 66/179 (37%) 57/209 (27%)
Low risk at present age 89/417 (21%) 60/340 (18%) 38/179 (21%) 40/209 (19%)
Rather not know 59/417 (14%) 37/340 (11%) 27/179 (15%) 33/209 (16%)
No reason given 51/417 (12%) 41/340 (12%) 18/179 (10%) 26/209 (12%)
Unpleasant test 28/417 (7%) 66/340 (19%) 2/179 (1%) 7/209 (3%)
Early diagnosis would not help 37/417 (9%) 12/340 (4%) 14/179 (8%) 22/209 (11%)
Harmful test 18/417 (4%) 39/340 (11%) 3/179 (2%) 3/209 (1%)
Inconvenient 20/417 (5%) 11/340 (3%) 6/179 (3%) 13/209 (6%)
Diﬃ  cult to access hospital 12/417 (3%) 5/340 (1%) 5/179 (3%) 8/209 (4%)
Table 6: Main reasons for choices
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urgent cancer referrals who transpire to have cancer) 
of 11%7 in the 2-week-wait clinics. Use of the 11% ﬁ gure is 
slightly misleading, because an average conversion rate 
means that some patients whose risk is below that ﬁ gure 
have been selected for investigation. No threshold level of 
risk warranting urgent investigation of cancer has been 
published, although the concept of a threshold is implicit 
in all UK guidance—and must be in excess of 1%. 
Our survey is also instructive about the referral process 
and the relationship between general practitioners and 
patients. As well as giving referral guidance, NICE 
guidelines emphasise the value and importance of 
including the patient in the decision-making process for 
referral and diagnostic testing for cancer; eﬀ ective 
communication is a key dimension of an appropriate 
referral.33 The way that participants engaged with our 
study, the subtle variations in participant preferences, 
and the high participant numbers suggest that general 
practitioners should be able to conﬁ dently engage in a 
dialogue with patients about the meaning of symptoms 
and the risk of cancer. General practitioners can 
underestimate the degree to which patients want 
information and to be involved in decision making,34 and 
decisions are sometimes made on the basis of a 
perception of what patients prefer,35 but our data and 
experience show that a substantial proportion of the 
population are willing to think about what symptoms 
mean, personal risk, and the possibility of cancer. This 
kind of internal dialogue could be used in the consulting 
room and turn aspirations about involvement of patients 
into a reality. Fear of cancer does not necessarily translate 
into a fear of talking about cancer.
The use of hypothetical vignettes has strengths and 
weaknesses. Much of the debate around their use centres 
on the degree to which responses can be used as accurate 
measures of views and behaviour, with the correlation 
between vignette response and actual behaviour being 
questioned.36 Conversely, several studies—eg, Peabody 
and colleagues’ investigation37—have shown that vignette 
responses are useful indicators of behaviour and 
compare favourably with other methods of assessments 
of preferences and intentions. The method has been 
widely used in the investigation of medical choice and 
judgment, such as by Jiwa and colleagues.38 Many 
participants in our study had not experienced referral for 
cancer testing and the vignettes provided a way to elicit 
preferences in the absence of direct experience.
Any questionnaire survey is only useful if the questions 
are realistic and the responses considered. We tried to 
ensure the vignettes were as realistic as possible and to 
make the percentage risk understandable by presenting 
it numerically and pictorially (see appendix for example), 
on the basis of suggestions from our two rounds of 
cognitive interviewing. We cannot know whether the 
overall high proportion of participants who would opt for 
investigation was driven by the symptom burden (which 
worsened with high risk levels) or by the risk level itself, 
or by a combination, although the last of these 
interpretations seems to be closest to clinical reality. We 
were realistic in our description of the three ﬁ rst-line 
investigations (colonoscopy, chest radiograph, and CT 
scanning), including their requirements and possible 
hazards (largely relevant to colonoscopy with its need for 
bowel preparation and the small risk of perforation). 
Since our study began, the ﬁ ndings of the SIGGAR 
study39 have suggested that CT colonography could be as 
accurate as colonoscopy; a higher proportion of 
participants in our study might have opted for 
investigation had this test been available. We made it 
clear that early diagnosis might not reduce the chance of 
death from lung and pancreatic cancers, emphasising 
that most patients would die of their disease, although 
prompt diagnosis could allow beneﬁ t from palliative 
care. Regarding the reliability of responses, the test–
retest analyses established that responses were 
consistent. We would also point to the reasons given for 
responses, which suggested that participants responded 
reﬂ ectively; the subtle variations around the type of test, 
risk, and the age of respondents showed an engagement 
with the diﬀ ering components of the vignette.
Ours was a large study, in which participants were 
recruited from urban, rural, wealthy, and deprived 
locations. Recruitment of 71% of individuals asked to 
participate is good for a questionnaire survey. Although 
our target population was the general UK population 
susceptible to cancer (adults aged ≥40 years), we made a 
pragmatic decision to recruit from waiting areas of 
general practices as opposed to other community 
settings. This decision enabled us to access a large group 
of people directly about a sensitive health-related subject. 
Moreover, a health-care setting provided the time, space, 
and privacy for respondents to complete the 
questionnaire thoughtfully. Reported data for the 
demographics of the population who attend primary 
Panel: Research in context
Systematic review
We searched OvidSP with the MeSH terms “patient preference”, “decision making”, “cancer”, 
“primary health care”, and “early diagnosis” for all reports published before Dec 12, 2013. 
We did not identify any studies that could be directly compared with our research because 
none reported patient or community preferences for cancer investigation. 
Interpretation
We have shown that members of the public have a clear preference for cancer 
investigations across a range of potential risk levels. Only in the case of colorectal cancer, 
with its invasive method of testing, did we record clear evidence of an association between 
a preference for testing and risk level, but even at the lowest risks, the proportion who 
would choose testing was more than 80%. Our study emphasises how the public and 
patients should be allowed to contribute directly to the continuing redesign of diagnostic 
pathways into and out of primary care for cancer in the UK. The way that people engaged 
with the survey and the vignettes of cancer symptoms draws attention to public 
willingness to discuss and contemplate risk of cancer and testing, which could potentially 
allow a more patient-centred primary-care consultation and decision-making process.
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care are scarce. The proportion with a past history of 
cancer in our sample (15%) is similar to the estimated 
proportion in the UK population of individuals older 
than 65 years (13%). This was not the case for ethnic 
origin, because the proportion of non-white individuals 
was clearly smaller than in the overall UK population. 
The small number of non-white individuals in our study 
means that the eﬀ ect of any ethnic variation is beyond 
the scope of this study.
NICE recommendations and National Health Service 
provision seem to diﬀ er greatly from preferences of 
patients in terms of cancer diagnostic pathways. Our 
ﬁ ndings should be considered during the revision of 
NICE guidance. In terms of clinical practice, our results 
should prompt careful thought about referral decision 
making. If more patients can be drawn into a full 
dialogue about preference, risk, and decision making 
with their general practitioner, a more eﬀ ective referral 
pathway from primary care could be created.
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